CorMedix Inc (CRMD):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:CorMedix Inc (CRMD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7982
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:52
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
CorMedix Inc (CorMedix) is a commercial-stage pharmaceutical company that develops and commercializes therapeutic products for prevention and treatment of cardiac, renal and infectious diseases. The company offers neutrolin, a non-antibiotic anti-infective developed as a preventative solution to decrease the threat of infection and blood clots in central venous catheters (CVCs). It offers neutrolin product, which act as novel formulation of taurolidine, citrate and heparin provides preventative solution by decreasing the triple threat of infection. CorMedix also develops therapeutic products for the prevention and treatment of inflammatory diseases. The company markets its products through its distribution network located across the US. CorMedix is headquartered in Berkeley Heights, New Jersey, the US.

CorMedix Inc (CRMD) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
CorMedix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
CorMedix Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
CorMedix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
CorMedix Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
CorMedix Inc, Medical Devices Deals, 2012 to YTD 2018 10
CorMedix Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
CorMedix Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
CorMedix Enters into Co-Development Agreement with POETIC for CRMD-005 12
Licensing Agreements 13
CorMedix Enters into Licensing Agreement with NanoProteagen 13
Equity Offering 14
Cormedix to Raise USD15.61 Million in Public Offering of Shares 14
CorMedix Files Registration Statement for Public Offering of Shares for up to USD70 Million 15
CorMedix Plans to Raise up to USD20 Million in Public Offering of Shares 16
CorMedix to Raise USD5 Million in Private Placement of Preferred Shares 17
CorMedix Raises USD14 Million in Public Offering of Shares and Warrants 18
CorMedix Raises USD28.45 Million in Public Offering of Shares 20
CorMedix Completes Private Placement Of Units For US$7.4 Million 21
CorMedix Completes Private Placement Of Shares For US$1.5 Million 22
CorMedix Completes Private Placement Of Shares For US$1.5 Million 24
CorMedix Announces Private Placement Of Shares For US$2 Million 26
CorMedix Files Registration Statement For Public Offering Of Securities For US$30 Million 27
Debt Offering 28
CorMedix Completes Final Tranche Of Private Placement Of Notes For US$0.5 Million 28
CorMedix Inc – Key Competitors 29
CorMedix Inc – Key Employees 30
CorMedix Inc – Locations And Subsidiaries 31
Head Office 31
Other Locations & Subsidiaries 31
Recent Developments 32
Financial Announcements 32
Aug 14, 2018: Cormedix reports second quarter financial results 32
May 15, 2018: Cormedix Announces First Quarter 2018 Financial Results 33
Mar 19, 2018: Cormedix Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Business Update 34
Nov 09, 2017: CorMedix Reports Third Quarter Financial Results and Provides Business Update 36
Aug 09, 2017: CorMedix Reports Second Quarter Financial Results and Provides Business Update 38
May 10, 2017: CorMedix Reports First Quarter Financial Results and Provides Business Update 40
Mar 17, 2017: Cormedix Reports fourth quarter and full year 2016 financial results and provides business update 41
Corporate Communications 42
Aug 31, 2018: CorMedix announces NYSE american acceptance of plan to regain listing compliance 42
Aug 25, 2017: CorMedix Announces a Change to its Senior Leadership 43
Aug 07, 2017: CorMedix Appoints Gary Gelbfish, M.D., to Board of Directors 44
Jun 26, 2017: Cormedix Appoints Mehmood Khan, M.D. And Steven Lefkowitz to its Board of Directors 45
Jun 12, 2017: Cormedix Announces Changes to Board of Directors 47
Mar 02, 2017: Cormedix Appoints John L. Armstrong to Senior Leadership Team 48
Feb 01, 2017: Cormedix Announces New Appointments to Senior Leadership Team 49
Product News 50
09/07/2017: CorMedix Presents Data Demonstrating Antimicrobial Activity of Taurolidine Against Potentially Deadly Fungal Pathogen Candida auris 50
Other Significant Developments 51
Feb 27, 2018: Cormedix provides update on its financing plans in connection with its ongoing lock-it 100 clinical study 51
Appendix 52
Methodology 52
About GlobalData 52
Contact Us 52
Disclaimer 52

List of Tables
CorMedix Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
CorMedix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
CorMedix Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
CorMedix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
CorMedix Inc, Deals By Therapy Area, 2012 to YTD 2018 9
CorMedix Inc, Medical Devices Deals, 2012 to YTD 2018 10
CorMedix Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
CorMedix Enters into Co-Development Agreement with POETIC for CRMD-005 12
CorMedix Enters into Licensing Agreement with NanoProteagen 13
Cormedix to Raise USD15.61 Million in Public Offering of Shares 14
CorMedix Files Registration Statement for Public Offering of Shares for up to USD70 Million 15
CorMedix Plans to Raise up to USD20 Million in Public Offering of Shares 16
CorMedix to Raise USD5 Million in Private Placement of Preferred Shares 17
CorMedix Raises USD14 Million in Public Offering of Shares and Warrants 18
CorMedix Raises USD28.45 Million in Public Offering of Shares 20
CorMedix Completes Private Placement Of Units For US$7.4 Million 21
CorMedix Completes Private Placement Of Shares For US$1.5 Million 22
CorMedix Completes Private Placement Of Shares For US$1.5 Million 24
CorMedix Announces Private Placement Of Shares For US$2 Million 26
CorMedix Files Registration Statement For Public Offering Of Securities For US$30 Million 27
CorMedix Completes Final Tranche Of Private Placement Of Notes For US$0.5 Million 28
CorMedix Inc, Key Competitors 29
CorMedix Inc, Key Employees 30
CorMedix Inc, Subsidiaries 31

List of Figures
CorMedix Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
CorMedix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
CorMedix Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
CorMedix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
CorMedix Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
CorMedix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
CorMedix Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
CorMedix Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[CorMedix Inc (CRMD):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Alliance Healthcare Services Inc:医療機器:M&Aディール及び事業提携情報
    Summary Alliance Healthcare Services Inc (Alliance Healthcare Services) is a provider of outsourced services including diagnostic imaging services. It provides a full line of services ranging from systems, technologists to operate the systems, sales and marketing, patient scheduling and pre-authoriz …
  • AcelRx Pharmaceuticals Inc (ACRX):企業の財務・戦略的SWOT分析
    AcelRx Pharmaceuticals Inc (ACRX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • SRF Ltd (SRF):企業の財務・戦略的SWOT分析
    SRF Ltd (SRF) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …
  • Nightstar Therapeutics PLC (NITE):製薬・医療:M&Aディール及び事業提携情報
    Summary Nightstar Therapeutics PLC (Nightstar Therapeutics), formerly Nightstar Therapeutics Ltd, is a clinical-stage gene therapy company. The company focus on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases. Its lead product cand …
  • Skechers U.S.A., Inc. (SKX):企業の財務・戦略的SWOT分析
    Skechers U.S.A., Inc. (SKX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Marubeni Corporation (8002)-石油・ガス分野:企業M&A・提携分析
    Summary Marubeni Corporation (Marubeni) is an integrated trading and investment business that operates through its domestic and overseas subsidiaries. It provides various products and commodities such as agri and marine products, chemicals, energy, metals and minerals, machinery, textiles, forest pr …
  • Exagen Diagnostics Inc-医療機器分野:企業M&A・提携分析
    Summary Exagen Diagnostics Inc (Exagen) is a medical device company that offers diagnostic tools. The company provides clinical tools for diagnosis, monitoring and prognosis of autoimmune connective tissue disease. Its products are used for therapeutic drug monitoring of hydroxychloroquine in whole …
  • CapitaLand Limited:企業のM&A・事業提携・投資動向
    CapitaLand Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's CapitaLand Limited Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), d …
  • Dialog Group Bhd (DIALOG):企業の財務・戦略的SWOT分析
    Dialog Group Bhd (DIALOG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • BB Biotech AG (BION):企業の財務・戦略的SWOT分析
    Summary BB Biotech AG (BB Biotech) operates as a financial service provider that offers biotechnology investments. The company invests in markets that develop new drugs and therapies for use in the treatment of autoimmune and infectious diseases, oncology disorders, cardiovascular diseases, and meta …
  • Arab Bank Plc (ARBK):企業の財務・戦略的SWOT分析
    Arab Bank Plc (ARBK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Intracom Holdings S.A. (INTRK):企業の財務・戦略的SWOT分析
    Intracom Holdings S.A. (INTRK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Charter Communications, Inc.:戦略・SWOT・企業財務分析
    Charter Communications, Inc. - Strategy, SWOT and Corporate Finance Report Summary Charter Communications, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • ImmunoCellular Therapeutics Ltd (IMUC)-医療機器分野:企業M&A・提携分析
    Summary ImmunoCellular Therapeutics Ltd (IMCU) is a clinical-stage biotechnology company which develops immune-based therapies for the treatment of various cancers. The product pipeline of the company includes active immunotherapies and patented monoclonal antibodies. IMCU’s immunotherapies product …
  • Linamar Corporation:企業の戦略・SWOT・財務分析
    Linamar Corporation - Strategy, SWOT and Corporate Finance Report Summary Linamar Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Strukton Groep Nv
    Strukton Groep Nv - Strategy, SWOT and Corporate Finance Report Summary Strukton Groep Nv - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Teijin Pharma Ltd-医療機器分野:企業M&A・提携分析
    Summary Teijin Pharma Ltd (Teijin Pharma), a subsidiary of Teijin Ltd develops, manufactures and markets pharmaceutical and home healthcare products. The company offers a range of pharmaceutical products for the treatment of bone and joint diseases, respiratory diseases and cardiovascular and metabo …
  • Strategic Energy Resources Ltd (SER):企業の財務・戦略的SWOT分析
    Summary Strategic Energy Resources Ltd (SER) is a mining company. It explores, develops, and produces mineral properties. The company product offerings include gold, copper and mineral sands. SER holds in Saxby gold project, Myall Creek project, Billa Kalina Copper-Gold Project and East Tennant copp …
  • Doutor Coffee Co. Ltd.:企業の戦略・SWOT・財務分析
    Doutor Coffee Co. Ltd. - Strategy, SWOT and Corporate Finance Report Summary Doutor Coffee Co. Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Societe Generale S.A.:戦略・SWOT・企業財務分析
    Societe Generale S.A. - Strategy, SWOT and Corporate Finance Report Summary Societe Generale S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆